KRAS and colorectal carcinoma: The KRAS G12C mutation is present in ~25% of NSCLCs [47, 48], but is less common in CRC (3–4%) [49]; however, patients with KRAS G12C-mutated CRC have a poor prognosis [50, 51], and drugs to quench RAS signaling offer a new therapeutic modality.